Ozempic and Wegovy (both semaglutide) work by mimicking the GLP-1 hormone
The result is chronically elevated blood triglycerides alongside expanding fat stores
The convenient format supports consistency and ease of daily use.* Metabolic & Wellness Support: GLP-1/GIP therapy may help support healthy glucose metabolism, insulin response, and overall metabolic efficiency when paired with healthy lifestyle habits.* Improved Confidence & Lifestyle Support: As patients progress toward their goals, many experience improvements in mobility, energy, confidence, and overall quality of life, supporting a healthier and more active lifestyle.* Encourages Healthier Eating Habits: By supporting appetite regulation and satiety, GLP-1/GIP therapy helps patients make healthier nutritional decisions and maintain improved portion control.* Supports Daily Energy & Motivation: Improved metabolic function and wellness support may contribute to increased daily energy, physical activity, and motivation to maintain healthier routines.* Provides a Comfortable Alternative to Injections: Sublingual oral drops remove the stress and inconvenience associated with needles, making treatment more approachable for many patients.* Pairs Well with Lifestyle Improvements: GLP-1/GIP therapy is most effective when combined with proper hydration, balanced nutrition, movement, and consistent wellness habits.* A Modern Approach to Wellness: GLP-1/GIP therapies represent one of the most advanced and clinically studied approaches to metabolic wellness and weight management available today.* Potential Side Effects: Some patients may experience mild gastrointestinal symptoms such as nausea, bloating, constipation, diarrhea, or stomach discomfort during the early stages of therapy
[DOI] [PubMed] [Google Scholar] 145.Chow L.S., Gerszten R.E., Taylor J.M., Pedersen B.K., van Praag H., Trappe S., Febbraio M.A., Galis Z.S., Gao Y., Haus J.M., et al
Anazco D, Fansa S, Hurtado MD, et al
In the largest pharmacogenomics GWAS of GLP-1 medications to date (15,237 participants, replicated in the All of Us cohort), researchers identified a missense variant in GLP1R the gene encoding the very receptor that semaglutide and tirzepatide bind that significantly predicts how much weight a person loses on treatment
